vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and Lakeside Holding Ltd (LSH). Click either name above to swap in a different company.
Lakeside Holding Ltd is the larger business by last-quarter revenue ($7.0M vs $3.9M, roughly 1.8× Opus Genetics, Inc.). On growth, Lakeside Holding Ltd posted the faster year-over-year revenue change (95.0% vs -10.2%).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
Lakeside Press was a Chicago publishing imprint under which the RR Donnelley Company produced fine books as well as mail order catalogs, telephone directories, encyclopedias, and advertising. The Press was best known for its high quality editions for the Chicago Caxton Club as well as the Lakeside Classics, a series of fine reprints.
IRD vs LSH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $7.0M |
| Net Profit | — | $-1.6M |
| Gross Margin | — | 27.2% |
| Operating Margin | — | -21.3% |
| Net Margin | — | -22.6% |
| Revenue YoY | -10.2% | 95.0% |
| Net Profit YoY | 53.0% | 18.7% |
| EPS (diluted) | — | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $7.0M | ||
| Q3 25 | $3.1M | $6.1M | ||
| Q2 25 | $2.9M | $6.3M | ||
| Q1 25 | $4.4M | $3.8M | ||
| Q4 24 | $4.3M | $3.6M | ||
| Q3 24 | $3.9M | $4.1M | ||
| Q2 24 | $1.1M | — | ||
| Q1 24 | $1.7M | — |
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $-17.5M | $-1.4M | ||
| Q2 25 | $-7.4M | $-893.1K | ||
| Q1 25 | $-8.2M | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $-7.5M | $-1.3M | ||
| Q2 24 | $-7.8M | — | ||
| Q1 24 | $-7.1M | — |
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -21.3% | ||
| Q3 25 | -269.9% | -20.8% | ||
| Q2 25 | -309.0% | -8.9% | ||
| Q1 25 | -227.2% | -28.2% | ||
| Q4 24 | — | -55.6% | ||
| Q3 24 | -207.1% | -32.5% | ||
| Q2 24 | -748.9% | — | ||
| Q1 24 | -450.5% | — |
| Q4 25 | — | -22.6% | ||
| Q3 25 | -566.9% | -22.2% | ||
| Q2 25 | -257.5% | -14.2% | ||
| Q1 25 | -187.5% | -28.2% | ||
| Q4 24 | — | -54.1% | ||
| Q3 24 | -194.6% | -32.7% | ||
| Q2 24 | -698.3% | — | ||
| Q1 24 | -415.3% | — |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.25 | $-0.09 | ||
| Q2 25 | $-0.12 | $-0.11 | ||
| Q1 25 | $-0.24 | $-0.14 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | $-0.29 | $-0.18 | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | $1.6M |
| Total DebtLower is stronger | — | $2.4M |
| Stockholders' EquityBook value | $15.3M | $12.2M |
| Total Assets | $50.2M | $24.3M |
| Debt / EquityLower = less leverage | — | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | $1.6M | ||
| Q3 25 | $30.8M | $4.5M | ||
| Q2 25 | $32.4M | $5.0M | ||
| Q1 25 | $41.8M | $1.5M | ||
| Q4 24 | $30.3M | $1.1M | ||
| Q3 24 | $36.6M | $2.7M | ||
| Q2 24 | $41.4M | — | ||
| Q1 24 | $47.2M | — |
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $15.3M | $12.2M | ||
| Q3 25 | $6.0M | $7.0M | ||
| Q2 25 | $17.5M | $2.8M | ||
| Q1 25 | $5.1M | $749.8K | ||
| Q4 24 | $6.7M | $1.6M | ||
| Q3 24 | $34.3M | $3.6M | ||
| Q2 24 | $40.6M | — | ||
| Q1 24 | $46.1M | — |
| Q4 25 | $50.2M | $24.3M | ||
| Q3 25 | $36.1M | $18.6M | ||
| Q2 25 | $38.7M | $14.4M | ||
| Q1 25 | $48.2M | $9.9M | ||
| Q4 24 | $36.9M | $9.8M | ||
| Q3 24 | $40.4M | $10.8M | ||
| Q2 24 | $44.8M | — | ||
| Q1 24 | $51.8M | — |
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $-453.5K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $-453.5K | ||
| Q3 25 | $-6.2M | $-4.0M | ||
| Q2 25 | $-10.3M | $-483.7K | ||
| Q1 25 | $-9.0M | $-238.3K | ||
| Q4 24 | $-25.6M | $-530.2K | ||
| Q3 24 | $-5.1M | $-1.4M | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $-5.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-497.4K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-560.5K | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -15.6% | ||
| Q3 24 | — | -34.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRD
Segment breakdown not available.
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
